PGE2 Ameliorates Aging-Aggravated Rotator Cuff Muscle Atrophy

Area of Science:

• Gerontology
• Muscle Physiology
• Mitochondrial Biology

Background:

• Aging exacerbates rotator cuff muscle degeneration, leading to atrophy and functional decline.
• Rotator cuff tears (RCTs) in aged individuals worsen muscle atrophy and fatty infiltration.
• Prostaglandin E2 (PGE2) is a key regulator of muscle regeneration.

Purpose of the Study:

• To investigate the role of PGE2 in age-related rotator cuff muscle degeneration and following RCT.
• To evaluate the therapeutic potential of inhibiting PGE2 degradation using SW033291.

Main Methods:

• Utilized young and aged C57BL/6J mice in sarcopenia and RCT models.
• Administered SW033291 to inhibit 15-prostaglandin dehydrogenase (15-PGDH), increasing PGE2 levels.
• Performed tissue staining, muscle mass, functional, and mitochondrial function assessments.

Main Results:

• Aging and RCTs induced muscle atrophy, reduced fiber cross-sectional area (CSA), and increased fatty infiltration.
• Aged mice with RCTs showed decreased muscle mass (45.45 ± 4.04 to 25.18 ± 1.82 mg) and CSA (1,697.3 ± 108.4 to 1,263.0 ± 56.8 μm²).
• SW033291 treatment increased PGE2 levels, reversed muscle atrophy (muscle mass: 33.50 ± 3.05 mg; CSA: 1,423.6 ± 81.3 μm²), and mitigated mitochondrial dysfunction.

Conclusions:

• Elevated PGE2 levels improve muscle health by reversing mitochondrial dysfunction.
• Inhibiting 15-PGDH is a viable therapeutic strategy for sarcopenia and enhancing rotator cuff repair.
• This study suggests a novel therapeutic approach for age-related muscle degeneration and RCT outcomes.